The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Efficacy and Safety of Epoetin Alfa in Critically Ill Patients
Open accessAbstract
BACKGROUND: Anemia, which is common in the critically ill, is often treated with red-cell transfusions, which are associated with poor clinical outcomes. We hypothesized that therapy with recombinant human erythropoietin (epoetin alfa) might reduce the need for red-cell transfusions. METHODS: In this prospective, randomized, placebo-controlled trial, we enrolled 1460 medical, surgical, or trauma patients between 48 and 96 hours after admission to the intensive care unit. Epoetin alfa (40,000 U) or placebo was administered weekly, for a maximum of 3 weeks; patients were followed for 140 days. The primary end point was the percentage of patients who received a red-cell transfusion. Secondary end points were the number of red-cell units transfused, mortality, and the change in hemoglobin concentration from baseline. RESULTS: As compared with the use of placebo, epoetin alfa therapy did not result in a decrease in either the number of patients who received a red-cell transfusion (relative risk for the epoetin alfa group vs. the placebo group, 0.95; 95% confidence interval [CI], 0.85 to 1.06) or the mean (+/-SD) number of red-cell units transfused (4.5+/-4.6 units in the epoetin alfa group and 4.3+/-4.8 units in the placebo group, P=0.42). However, the hemoglobin concentration at day 29 increased more in the epoetin alfa group than in the placebo group (1.6+/-2.0 g per deciliter vs. 1.2+/-1.8 g per deciliter, P<0.001). Mortality tended to be lower at day 29 among patients receiving epoetin alfa (adjusted hazard ratio, 0.79; 95% CI, 0.56 to 1.10); this effect was also seen in prespecified analyses in those with a diagnosis of trauma (adjusted hazard ratio, 0.37; 95% CI, 0.19 to 0.72). A similar pattern was seen at day 140 (adjusted hazard ratio, 0.86; 95% CI, 0.65 to 1.13), particularly in those with trauma (adjusted hazard ratio, 0.40; 95% CI, 0.23 to 0.69). As compared with placebo, epoetin alfa was associated with a significant increase in the incidence of thrombotic events (hazard ratio, 1.41; 95% CI, 1.06 to 1.86). CONCLUSIONS: The use of epoetin alfa does not reduce the incidence of red-cell transfusion among critically ill patients, but it may reduce mortality in patients with trauma. Treatment with epoetin alfa is associated with an increase in the incidence of thrombotic events. (ClinicalTrials.gov number, NCT00091910 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
Hébert, P. C., Wells, G., Blajchman, M. A., Marshall, J., Martin, C., Pagliarello, G., Tweeddale, M., Schweitzer, I., & Yetisir, E. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400601 · Cited by 5,187
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care
(1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401322 · Cited by 2,037
Anemia and Blood Transfusion in Critically Ill Patients
Vincent, J. L. (2002) · JAMA · doi:10.1001/jama.288.12.1499 · Cited by 1,821
Corwin, H. L., Gettinger, A., Pearl, R. G., Fink, M. P., Levy, M. M., Abraham, E., MacIntyre, N. R., Shabot, M. M., Duh, M.-S., & Shapiro, M. J. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000104112.34142.79 · Cited by 1,348
Self-citationHenke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250
Effect of Stored-Blood Transfusion on Oxygen Delivery in Patients With Sepsis
Marik, P. E. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500230106037 · Cited by 812
Leyland-Jones, B., Semiglazov, V., Pawlicki, M., Pienkowski, T., Tjulandin, S., Manikhas, G., Makhson, A., Roth, A., Dodwell, D., Baselga, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.150 · Cited by 668
Phrommintikul, A., Haas, S. J., Elsik, M., & Krum, H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60194-9 · Cited by 638
Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., Trelle, S., Weingart, O., Bayliss, S., Djulbegovic, B., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj189 · Cited by 548
Research works printed but not linked: 1
- 10.1001/jama.269.23.3024 · doi:10.1001/jama.269.23.3024
Cited by
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
Spahn, D. R., Bouillon, B., Cerny, V., Duranteau, J., Filipescu, D., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,269
Bohlius, J., Schmidlin, K., Brillant, C., Schwarzer, G., Trelle, S., Seidenfeld, J., Zwahlen, M., Clarke, M., Weingart, O., Kluge, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60502-x · Cited by 597
Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care*
Napolitano, L. M., Kurek, S., Luchette, F. A., Corwin, H. L., Barie, P. S., Tisherman, S. A., Hebert, P. C., Anderson, G. L., Bard, M. R., Bromberg, W., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181b39f1b · Cited by 551
Self-citationLitton, E., Xiao, J., & Ho, K. M. (2013) · BMJ · doi:10.1136/bmj.f4822 · Cited by 394
Bleeding, Blood Transfusion, and Increased Mortality After Percutaneous Coronary Intervention
Doyle, B. J., Rihal, C. S., Gastineau, D. A., & Holmes, D. R. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.073 · Cited by 392
The non‐haematopoietic biological effects of erythropoietin
Arcasoy, M. O. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07014.x · Cited by 347
Brines, M., & Cerami, A. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02024.x · Cited by 333
Blood Transfusion and Infection After Cardiac Surgery
Horvath, K. A., Acker, M. A., Chang, H., Bagiella, E., Smith, P. K., Iribarne, A., Kron, I. L., Lackner, P., Argenziano, M., Ascheim, D. D., et al. (2013) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.11.078 · Cited by 306
Jädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4906 · Cited by 300
Anemia, Blood Loss, and Blood Transfusions in North American Children in the Intensive Care Unit
Bateman, S. T., Lacroix, J., Boven, K., Forbes, P., Barton, R., Thomas, N. J., Jacobs, B., Markovitz, B., Goldstein, B., Hanson, J. H., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1637oc · Cited by 287
Anemia in Critical Illness: Insights into Etiology, Consequences, and Management
Hayden, S. J., Albert, T. J., Watkins, T. R., & Swenson, E. R. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1915ci · Cited by 271
Vlaar, A. P., Oczkowski, S., de Bruin, S., Wijnberge, M., Antonelli, M., Aubron, C., Aries, P., Duranteau, J., Juffermans, N. P., Meier, J., et al. (2020) · Intensive Care Medicine · doi:10.1007/s00134-019-05884-8 · Cited by 284
Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial
Nichol, A., French, C., Little, L., Haddad, S., Presneill, J., Arabi, Y., Bailey, M., Cooper, D. J., Duranteau, J., Huet, O., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00386-4 · Cited by 272
Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients
Retter, A., Wyncoll, D., Pearse, R., Carson, D., McKechnie, S., Stanworth, S., Allard, S., Thomas, D., Walsh, T., & British Committee for Standards in Haematology (2013) · British Journal of Haematology · doi:10.1111/bjh.12143 · Cited by 258
Nairz, M., Schroll, A., Moschen, A. R., Sonnweber, T., Theurl, M., Theurl, I., Taub, N., Jamnig, C., Neurauter, D., Huber, L. A., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.002 · Cited by 194
The pleiotropic effects of erythropoietin in infection and inflammation
Nairz, M., Sonnweber, T., Schroll, A., Theurl, I., & Weiss, G. (2012) · Microbes and Infection · doi:10.1016/j.micinf.2011.10.005 · Cited by 161
Wallach, J. D., Sullivan, P. G., Trepanowski, J. F., Sainani, K. L., Steyerberg, E. W., & Ioannidis, J. P. A. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9125 · Cited by 148
Outcome based subgroup analysis: a neglected concern
Hirji, K. F., & Fagerland, M. W. (2009) · Trials · doi:10.1186/1745-6215-10-33 · Cited by 41
“[20] examined this issue by randomizing 1460 cases in an intensive care facility to either epoetin alfa (n = 733) or placebo (n = 727).”
BackgroundCombination therapies for traumatic brain injury: prospective considerations
Margulies, S. S., & Hicks, R. (2009) · Journal of Neurotrauma · doi:10.1089/neu.2008-0794 · Cited by 22
Metadata
- Authors
- Corwin, H. L., Gettinger, A., Fabian, T. C., May, A., Pearl, R. G., Heard, S., An, R., Bowers, P. J., Burton, P., Klausner, M. A., & Corwin, M. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-06
- Volume
- 357
- Issue
- 10
- Pages
- 965-976
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170110528
- Cited by
- 545
- References
- 25
- FWCI
- 31.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.